伴随诊断面临的未来挑战。 - Suppr

Suppr

超能文献

Challenges ahead for companion diagnostics.

作者信息

Schmidt Charlie

出版信息

J Natl Cancer Inst. 2012 Jan 4;104(1):14-5. doi: 10.1093/jnci/djr535. Epub 2011 Dec 14.

DOI:10.1093/jnci/djr535

PMID:22173588

Abstract

摘要

相似文献

Challenges ahead for companion diagnostics.

J Natl Cancer Inst. 2012 Jan 4;104(1):14-5. doi: 10.1093/jnci/djr535. Epub 2011 Dec 14.

Early accelerated approval for highly targeted cancer drugs.

N Engl J Med. 2011 Mar 24;364(12):1087-9. doi: 10.1056/NEJMp1100548.

FDA approves vemurafenib for treatment of metastatic melanoma.

Oncology (Williston Park). 2011 Sep;25(10):906.

Personalized-medicine trials on the rise.

J Natl Cancer Inst. 2012 Oct 3;104(19):1425-6. doi: 10.1093/jnci/djs432. Epub 2012 Sep 24.

Larger companies dominate cancer companion diagnostic approvals.

Nat Biotechnol. 2011 Nov 8;29(11):955-7. doi: 10.1038/nbt1111-955.

Special report: companion diagnostics--example of BRAF gene mutation testing to select patients with melanoma for treatment with BRAF kinase inhibitors.

Technol Eval Cent Assess Program Exec Summ. 2011 Nov;26(7):1-5.

Drug approvals 2011: focus on companion diagnostics.

J Natl Cancer Inst. 2012 Jan 18;104(2):84-6. doi: 10.1093/jnci/djr552. Epub 2012 Jan 3.

More Than One Way to Measure? A Casuistic Approach to Cancer Clinical Trials.

Perspect Biol Med. 2018;61(2):174-190. doi: 10.1353/pbm.2018.0035.

Clin Cancer Res. 2014 Mar 15;20(6):1445-52. doi: 10.1158/1078-0432.CCR-13-1761.

Strides in melanoma announced: maximizing value comes next.

J Natl Cancer Inst. 2011 Jul 6;103(13):997-9. doi: 10.1093/jnci/djr254. Epub 2011 Jun 21.

引用本文的文献

Could a revision of the current guidelines for cancer drug use improve the quality of cancer treatment?

Ther Clin Risk Manag. 2014 Jan 30;10:69-72. doi: 10.2147/TCRM.S51404. eCollection 2014.

A rational free energy-based approach to understanding and targeting disease-causing missense mutations.

J Am Med Inform Assoc. 2013 Jul-Aug;20(4):643-51. doi: 10.1136/amiajnl-2012-001505. Epub 2013 Feb 13.

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma.

Cancer Manag Res. 2012;4:243-52. doi: 10.2147/CMAR.S25284. Epub 2012 Aug 8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Challenges ahead for companion diagnostics.

J Natl Cancer Inst. 2012 Jan 4;104(1):14-5. doi: 10.1093/jnci/djr535. Epub 2011 Dec 14.

Early accelerated approval for highly targeted cancer drugs.

N Engl J Med. 2011 Mar 24;364(12):1087-9. doi: 10.1056/NEJMp1100548.

FDA approves vemurafenib for treatment of metastatic melanoma.

Oncology (Williston Park). 2011 Sep;25(10):906.

Personalized-medicine trials on the rise.

J Natl Cancer Inst. 2012 Oct 3;104(19):1425-6. doi: 10.1093/jnci/djs432. Epub 2012 Sep 24.

Larger companies dominate cancer companion diagnostic approvals.

Nat Biotechnol. 2011 Nov 8;29(11):955-7. doi: 10.1038/nbt1111-955.

Special report: companion diagnostics--example of BRAF gene mutation testing to select patients with melanoma for treatment with BRAF kinase inhibitors.

Technol Eval Cent Assess Program Exec Summ. 2011 Nov;26(7):1-5.

Drug approvals 2011: focus on companion diagnostics.

J Natl Cancer Inst. 2012 Jan 18;104(2):84-6. doi: 10.1093/jnci/djr552. Epub 2012 Jan 3.

More Than One Way to Measure? A Casuistic Approach to Cancer Clinical Trials.

Perspect Biol Med. 2018;61(2):174-190. doi: 10.1353/pbm.2018.0035.

Clin Cancer Res. 2014 Mar 15;20(6):1445-52. doi: 10.1158/1078-0432.CCR-13-1761.

Strides in melanoma announced: maximizing value comes next.

J Natl Cancer Inst. 2011 Jul 6;103(13):997-9. doi: 10.1093/jnci/djr254. Epub 2011 Jun 21.

引用本文的文献

Could a revision of the current guidelines for cancer drug use improve the quality of cancer treatment?

Ther Clin Risk Manag. 2014 Jan 30;10:69-72. doi: 10.2147/TCRM.S51404. eCollection 2014.

A rational free energy-based approach to understanding and targeting disease-causing missense mutations.

J Am Med Inform Assoc. 2013 Jul-Aug;20(4):643-51. doi: 10.1136/amiajnl-2012-001505. Epub 2013 Feb 13.

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma.

Cancer Manag Res. 2012;4:243-52. doi: 10.2147/CMAR.S25284. Epub 2012 Aug 8.